Inhaler
Latest Novartis AG Patents:
- Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
- CD19 and CD22 chimeric antigen receptors and uses thereof
- Tricyclic AKR1C3 dependent KARS inhibitors
- Treatment of cancer using GFR alpha-4 chimeric antigen receptor
- Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant FC fusion proteins
Description
FIG. 1 front and side perspective view;
FIG. 2 side perspective view;
FIG. 3 bottom perspective view; and,
FIG. 4 top perspective view.
Referenced Cited
Patent History
Patent number: D410541
Type: Grant
Filed: Dec 22, 1997
Date of Patent: Jun 1, 1999
Assignee: Novartis AG (Basel)
Inventor: Claude Moulin (Rheinfelden)
Primary Examiner: Stella Reid
Assistant Examiner: I Simmons
Attorneys: Stephen G. Kalinchak, William K. Wissing
Application Number: 0/80,996
Type: Grant
Filed: Dec 22, 1997
Date of Patent: Jun 1, 1999
Assignee: Novartis AG (Basel)
Inventor: Claude Moulin (Rheinfelden)
Primary Examiner: Stella Reid
Assistant Examiner: I Simmons
Attorneys: Stephen G. Kalinchak, William K. Wissing
Application Number: 0/80,996
Classifications
Current U.S. Class:
Respirator, Vaporizer, Or Inhalation Tube (4) (D24/110)
International Classification: 2404;
International Classification: 2404;